跳至主要内容
临床试验/CTRI/2014/12/005265
CTRI/2014/12/005265招募中3 期

Randomized placebo controlled study of the effect of Ranolazine on HbA1c level in Type 2 diabetes mellitus

IPGMER1 个研究点 分布在 1 个国家目标入组 86 人开始时间: 2013年10月7日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
86
试验地点
1
主要终点
Change from baseline in HbA1c at Week 12

研究概览

简要总结

Diabetes mellitus has become endemic in India.It predisposes to microvascular, macrovascular complications leading to  coronarysyndromes , cerebrovascular accidents, retinopathy, nephropathy, & and manyother diseases.

Ranolazine – a drug approved to be used in coronarysyndromes, showed to improve glycemic control in CARISA TRIAL. Mechanism ofaction of glycemic control is yet to be explored.

So a study is planned to evaluate the effect ofranolazine on HbA1c, fasting glucose, serum insulin, & C-Peptide. The studydesign would be a randomized placebo controlled trial. Study population wouldbe patients attending diabetic clinic of IPGME&R & SSKM Hospital,Kolkata. Target sample size will be 34 patients in each group suffering fromtype 2 Diabetes currently on  non-insulinantidiabetic therapy (Metformin)  inaddition to diet and exercise.

After obtaining written informed consent from eitherpatient, subjects would be randomly allocated to two groups – one to receiveranolazine and the other to receive placebo as add on to standard oralhypoglycemic medication (Metformin).

Data would be analyzed in the Department ofPharmacology, IPGME&R and the results will be compiled into the doctoralthesis.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • •18 to65 years old •Subjects with T2DM currently on non-insulin antidiabetic therapy (metformin) in addition to diet and exercise •Body mass index (BMI) ≥ 20 kg/m2 and ≤ 35 kg/m2 •HbA1c
  • 10% •Female of child-bearing potential must agree to use effective methods of contraception •Signed written informed consent.

排除标准

  • 未提供

结局指标

主要结局

Change from baseline in HbA1c at Week 12

时间窗: 12 weeks

Change from baseline in 2-hour postprandial serum glucose at Week 12

时间窗: 12 weeks

Change from baseline in fasting serum glucose at Week 12

时间窗: 12 weeks

次要结局

  • Change from baseline in fasting serum C-peptide at Weeks 12(Change from baseline in fasting serum insulin at Weeks 12)

研究者

发起方
IPGMER
申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验

Effect of Ranolazine on control of Diabetes Mellitus | 临床试验